To our surprise, similar to anti-PD-L1 therapy, OSMI-1 alone significantly inhibited MC38 tumor growth and survival, and the combination of OSMI-1 and anti-PD-L1 therapy resulted in superior tumor suppression compared with monotherapy (Fig. 7E–F). Here, CD274 is linked to neoplasm.